Peter C Enzinger

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. Enzinger P, Burtness B, Niedzwiecki D, Ye X, Douglas K, Ilson D, et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34:2736-42 pubmed publisher
    ..Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. ..
  2. Cleary J, Mamon H, Szymonifka J, Bueno R, Choi N, Donahue D, et al. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016;16:468 pubmed publisher
    ..Further studies adding celecoxib to neoadjuvant chemoradiation in esophageal cancer are not warranted. Clinicaltrials.gov: NCT00137852 , registered August 29, 2005. ..

Detail Information

Publications2

  1. Enzinger P, Burtness B, Niedzwiecki D, Ye X, Douglas K, Ilson D, et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34:2736-42 pubmed publisher
    ..Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. ..
  2. Cleary J, Mamon H, Szymonifka J, Bueno R, Choi N, Donahue D, et al. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016;16:468 pubmed publisher
    ..Further studies adding celecoxib to neoadjuvant chemoradiation in esophageal cancer are not warranted. Clinicaltrials.gov: NCT00137852 , registered August 29, 2005. ..